Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price Expected to Rise, UBS Group Analyst Says

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target lifted by UBS Group from $595.00 to $660.00 in a note issued to investors on Friday,Benzinga reports. The brokerage presently has a “neutral” rating on the biopharmaceutical company’s stock. UBS Group’s target price suggests a potential upside of 1.91% from the company’s previous close.

Other research analysts also recently issued reports about the stock. Cantor Fitzgerald lifted their target price on shares of Regeneron Pharmaceuticals from $678.00 to $740.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 29th. Morgan Stanley lowered their price objective on shares of Regeneron Pharmaceuticals from $761.00 to $756.00 and set an “overweight” rating on the stock in a research report on Friday, October 10th. Weiss Ratings reissued a “hold (c-)” rating on shares of Regeneron Pharmaceuticals in a research note on Wednesday, October 8th. Wall Street Zen raised Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, November 1st. Finally, Citigroup lifted their price target on Regeneron Pharmaceuticals from $660.00 to $700.00 and gave the company a “buy” rating in a report on Wednesday, October 29th. Three equities research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $796.57.

Regeneron Pharmaceuticals Price Performance

REGN stock traded up $0.76 on Friday, hitting $647.63. 290,798 shares of the company’s stock traded hands, compared to its average volume of 1,093,477. The stock has a market cap of $68.64 billion, a price-to-earnings ratio of 15.50, a P/E/G ratio of 2.03 and a beta of 0.31. Regeneron Pharmaceuticals has a 1-year low of $476.49 and a 1-year high of $834.42. The company has a current ratio of 4.06, a quick ratio of 3.72 and a debt-to-equity ratio of 0.09. The stock has a fifty day moving average of $586.50 and a 200-day moving average of $567.49.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Tuesday, October 28th. The biopharmaceutical company reported $11.83 EPS for the quarter, beating analysts’ consensus estimates of $9.73 by $2.10. The company had revenue of $3.75 billion during the quarter, compared to the consensus estimate of $3.57 billion. Regeneron Pharmaceuticals had a return on equity of 13.76% and a net margin of 32.13%.The company’s quarterly revenue was up .9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $12.46 EPS. On average, analysts forecast that Regeneron Pharmaceuticals will post 35.92 EPS for the current fiscal year.

Insider Activity

In other Regeneron Pharmaceuticals news, Director Christine A. Poon sold 6,500 shares of the business’s stock in a transaction dated Wednesday, October 29th. The shares were sold at an average price of $654.27, for a total value of $4,252,755.00. Following the completion of the transaction, the director directly owned 2,352 shares of the company’s stock, valued at approximately $1,538,843.04. The trade was a 73.43% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 7.02% of the company’s stock.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in the company. NEOS Investment Management LLC boosted its holdings in Regeneron Pharmaceuticals by 50.3% in the third quarter. NEOS Investment Management LLC now owns 48,173 shares of the biopharmaceutical company’s stock valued at $27,086,000 after acquiring an additional 16,123 shares during the last quarter. GSA Capital Partners LLP lifted its position in Regeneron Pharmaceuticals by 65.2% during the 3rd quarter. GSA Capital Partners LLP now owns 3,440 shares of the biopharmaceutical company’s stock valued at $1,934,000 after purchasing an additional 1,358 shares during the period. Rothschild Investment LLC boosted its stake in shares of Regeneron Pharmaceuticals by 51.1% in the 3rd quarter. Rothschild Investment LLC now owns 609 shares of the biopharmaceutical company’s stock valued at $342,000 after purchasing an additional 206 shares during the last quarter. Merit Financial Group LLC boosted its stake in shares of Regeneron Pharmaceuticals by 302.4% in the 3rd quarter. Merit Financial Group LLC now owns 1,859 shares of the biopharmaceutical company’s stock valued at $1,045,000 after purchasing an additional 1,397 shares during the last quarter. Finally, denkapparat Operations GmbH acquired a new stake in shares of Regeneron Pharmaceuticals during the 3rd quarter worth approximately $409,000. 83.31% of the stock is owned by institutional investors and hedge funds.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.